A reduced adiponectin serum level has also been identified in patients with metastatic kidney cancer, while a high preoperative adiponectin serum level has been associated with an 83% decrease in risk of death in RCC patients [17,54]. Here, ADIPOQ is linked to renal cell carcinoma.